AI in GMP Manufacturing: Are Regulators Ready for Digital Factories?

Machine learning and AI in GMP manufacturing are already supporting predictive maintenance, process monitoring, quality control, and manufacturing optimisation across pharmaceutical production.

However, the technology is advancing faster than the regulatory frameworks needed to govern it. The challenge is how AI can be implemented while maintaining Good Manufacturing Practice (GMP) compliance.

Image

Why AI Is Essential for Modern Pharmaceutical Manufacturing

Pharmaceutical manufacturing is generating unprecedented volumes of data. Continuous manufacturing systems, process analytical technology (PAT), digital twins, and connected manufacturing equipment now produce millions of data points throughout the production lifecycle.

Traditional statistical methods struggle to interpret this complexity in real time. AI and ML offer a different approach by recognising patterns, predicting deviations, and supporting faster operational decisions.

AI applications are expanding across multiple GMP functions, including:

• Real-time process monitoring
• Predictive equipment maintenance
• Automated quality control
• Batch release decision support
• Supply chain optimisation
• Manufacturing process optimisation

Rather than replacing GMP systems, AI has the potential to strengthen quality assurance by identifying emerging risks before they affect product quality or patient safety.

The Biggest Challenge Is No Longer Technology; It’s Regulation

Regulation is one of the primary barriers to wider AI adoption.

Unlike conventional software, many machine learning models continue to evolve after deployment. This creates uncertainty for pharmaceutical manufacturers because GMP validation traditionally assumes that validated systems remain stable unless formally changed.

There are several regulatory questions that manufacturers must address before AI can become routine within GMP environments. These issues require updated regulatory guidance rather than entirely new GMP principles.

Existing quality concepts, including validation, documentation, and risk management, remain applicable but must evolve alongside AI technologies.

Model validation

How should regulators validate machine learning systems that learn from new manufacturing data over time?

Data integrity

AI systems depend on high-quality, representative datasets. Incomplete, biased, or poorly governed manufacturing data could reduce model reliability and introduce quality risks.

Explainability

Many advanced AI models operate as “black boxes”. Manufacturers and regulators need sufficient transparency to understand how important GMP decisions are generated.

Change control

If an AI model updates continuously, manufacturers must determine when retraining constitutes a GMP-regulated system change requiring revalidation.

View interview AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

Image

Risk-Based Governance Will Define Successful AI Adoption

Rather than treating every AI application equally, a risk-based regulatory approach is recommended.

Lower-risk applications, such as predictive maintenance or inventory forecasting, may require relatively limited regulatory oversight.

By contrast, AI systems influencing product quality, critical process parameters, or batch disposition should receive much greater scrutiny.

There are several principles that could support compliant implementation. Together, these measures create an auditable framework that aligns AI implementation with existing GMP expectations.

Strong data governance

Reliable AI begins with reliable manufacturing data. Organisations should establish clear controls for data quality, integrity, traceability, and cybersecurity.

Lifecycle validation

Validation should extend beyond initial deployment to include ongoing performance monitoring, periodic review, and model retraining where appropriate.

Human oversight

AI should support, rather than replace, qualified GMP personnel. Critical manufacturing decisions should continue to involve appropriately trained human reviewers.

Comprehensive documentation

Manufacturers should maintain complete records covering model development, training datasets, validation activities, algorithm updates, and system performance throughout the AI lifecycle.

Regulators Are Already Moving Towards AI Governance

Although comprehensive AI-specific GMP regulations are still emerging, international regulatory agencies have already begun laying the groundwork.

Increasing activity from organisations including:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• International Council for Harmonisation (ICH)
• Pharmaceutical Inspection Co-operation Scheme (PIC/S)

Many existing digitalisation initiatives, including ICH Q9 (Quality Risk Management), ICH Q10 (Pharmaceutical Quality System), and FDA guidance on advanced manufacturing technologies, already provide principles that can be extended to AI-enabled manufacturing systems.

Rather than requiring a completely new regulatory framework, future guidance will likely adapt established GMP concepts to accommodate intelligent software capable of continuous learning. 

Image

Building Trust in AI-Driven Pharmaceutical Manufacturing

AI has the potential to become a foundational technology across pharmaceutical manufacturing, improving operational efficiency, process consistency, and product quality. However, widespread adoption will depend on building regulatory confidence alongside technological capability.

For manufacturers, success will rely on combining robust data governance, lifecycle validation, transparent algorithms, and human oversight within existing pharmaceutical quality systems. Organisations that establish these capabilities early are likely to be better positioned as AI-specific regulatory expectations continue to evolve.

AI implementation is a quality, compliance, and governance priority that will shape the future of GMP manufacturing.

At Pharmatica, we analyse the technologies, regulatory developments, and operational strategies transforming pharmaceutical manufacturing. From AI-enabled production and continuous manufacturing to digital quality systems and advanced GMP compliance, we help life sciences leaders translate emerging innovation into practical operational advantage.

Pharmatica: Insight. Connection. Impact.